Neuropharmacology
January 21, 2023
Edward M. Sellers, Myroslava K. Romach
21 citations
The substantial challenges facing high and low dose psychedelic drug development to achieve regulatory approval have been documented in the scientific literature. These limitations have not deterred drug developers and social media from repeatedly misleading patients, the public and health professionals. Developing "micro doses" of psychedelics overcomes many of the scientific and regulatory...
Journal of Psychedelic Studies
January 18, 2023
Benjamin R. Lewis, Kevin Byrne, John Hendrick et al.
22 citations
Abstract Background Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential distress associated with serious medical illness and has generally been employed on an individual basis, which presents challenges for scaling and resource availability. There are also compelling theoretical reasons to suggest that group-based...
January 16, 2023
Daisy Lutyens
1 citation
<p>Examining participants’ experiences self-medicating with LSD, psilocybin, and MDMA, this exploratory study sought to determine whether psychedelics have a future in New Zealand mental health treatment. This thesis employed a mixed-methods approach to data collection, by collecting broad-brush quantitative data via a Qualtrics survey, which then informed the qualitative data collection method...
Journal of Psychedelic Studies
January 16, 2023
Benjamin A. Korman
7 citations
Abstract Background and aims Although large-scale population studies have linked the use of classic psychedelics (lysergic acid diethylamide, psilocybin, or mescaline) to reduced odds of physical health problems, mental health problems, and criminal behavior, the roughly 35 million adults in the United States who have used classic psychedelics are nonetheless stigmatized in the American job...
Annals of Pharmacotherapy
January 12, 2023
C Michael White, Nissen Weisman, Joseph Dalo
18 citations
Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca. Study Selection and Data Extraction: Studies assessing patients with cancer receiving...
International Journal of Molecular Sciences
January 10, 2023
Andrea Mastinu, Margrate Anyanwu, Marinella Carone et al.
45 citations
The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics. For several years there has been growing interest among psychotherapists in psilocybin or lysergic acid...
Frontiers in Psychiatry
January 10, 2023
Jonina Rabinowitz, Raz Gross, Shaul Lev-Ran
15 citations
Objective Classic psychedelics (LSD, psilocybin, and peyote/mescaline) have been used to support addiction treatment in a variety of contexts ranging from ceremonial use to clinical trials. The aim of this study was to test the hypothesis that past naturalistic use of classic psychedelics would be associated with decreased prevalence of substance use disorder, when controlling for known...
Pain Practice
January 4, 2023
Tim Willegers, Anke Reuser, Cornelis Kramers et al.
38 citations
Abstract Aims We aim to provide an evidence‐based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. Content Chronic pain is a common and complex problem, with an unknown etiology. Psychedelics like lysergic acid diethylamide (LSD) and psilocybin, may play a role in the management of chronic pain. Through activation of the serotonin‐2A (5‐HT2A) receptor,...
Journal of Psychoactive Drugs
2023
Aviad Hadar, Jonathan David, Nadav Shalit et al.
93 citations
Psychedelics were used in the treatment of psychiatric conditions prior to their prohibition in the late 1960s. In the past three decades, there is a revived research interest in the therapeutic potential of psychedelic drugs with expected FDA approvals for treatment of various conditions. Given the exponential scientific growth of this field, we sought to characterize, analyze, and visualize...
Drug Science, Policy and Law
2023
Adriana D’arienzo, Giorgio Samorini
In recent years, the historical record of psychedelic therapy in Europe and the Americas has undergone considerable revision. In this article, we contribute to this re-interpretation by sharing documentation relating to psychedelic therapy carried out in Italy during the period 1927–1966. Our library research has uncovered one hundred publications, documenting at least 60 clinical studies in...